189 related articles for article (PubMed ID: 25501128)
1. Stem cells increase in numbers in perinecrotic areas in human renal cancer.
Varna M; Gapihan G; Feugeas JP; Ratajczak P; Tan S; Ferreira I; Leboeuf C; Setterblad N; Duval A; Verine J; Germain S; Mongiat-Artus P; Janin A; Bousquet G
Clin Cancer Res; 2015 Feb; 21(4):916-24. PubMed ID: 25501128
[TBL] [Abstract][Full Text] [Related]
2. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
6. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
7. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
8. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
Karam JA; Zhang XY; Tamboli P; Margulis V; Wang H; Abel EJ; Culp SH; Wood CG
Eur Urol; 2011 Apr; 59(4):619-28. PubMed ID: 21167632
[TBL] [Abstract][Full Text] [Related]
10. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
11. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Gao H; Jiang Q; Han Y; Peng J; Wang C
Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
13. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
14. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
[TBL] [Abstract][Full Text] [Related]
15. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
Robinson SP; Boult JKR; Vasudev NS; Reynolds AR
Cancer Res; 2017 Aug; 77(15):4127-4134. PubMed ID: 28566330
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
20. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance.
Berkers J; Govaere O; Wolter P; Beuselinck B; Schöffski P; van Kempen LC; Albersen M; Van den Oord J; Roskams T; Swinnen J; Joniau S; Van Poppel H; Lerut E
J Urol; 2013 May; 189(5):1930-8. PubMed ID: 23206420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
